Preclinical multimodality phantom design for quality assurance of tumor size measurement.

ABSTRACT:

Background

Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.

Methods

Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UT

SUBMITTER: Lee YC 

PROVIDER: S-EPMC3206432 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature